Nuvation Bio Inc.

Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on oncology drug discovery and development. The company went public through a de-SPAC merger with Panacea Acquisition Corp. II, a healthcare-focused blank-check vehicle that held its initial public offering in 2020 and was sponsored by Panacea Acquisition Holdings II LLC. This 10-Q quarterly report was filed with the SEC on November 16, 2020, under accession number 0001213900-20-037163, covering the company's financial position ahead of the transaction close. Operating in the life sciences and healthcare sector, the combined entity subsequently traded on a major U.S. exchange under the ticker NUVB. Sign up for full data on SpacDesk to access complete filing histories, deal timelines, and analytics across the entire SPAC universe.